Effect of histidine-tag and R457H and E580Q mutations on catalytic activity of recombinant human cytochrome P450 oxidoreductase

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 1, 2012, Pages 150-154

  Niwa, Toshiro ^a   Minami, Katsuhito ^a   Katagiri, Masanao ^a  

^a OSAKA KYOIKU UNIVERSITY   (Japan)

Author keywords

Cytochrome c reduction; Cytochrome P450 oxidoreductase; E580Q variant; Histidine tag; NADPH oxidation; R457H variant

Indexed keywords

CYTOCHROME P450 REDUCTASE; POLYHISTIDINE TAG; RECOMBINANT CYTOCHROME P450 REDUCTASE; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME METABOLISM; EXPRESSION VECTOR; GENE MUTATION; GENETIC VARIABILITY; NONHUMAN; NOTE; PLASMID; REDUCTION KINETICS; WILD TYPE;

EID: 84857756638     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-NT-102     Document Type: Article

References (15)

1. Hart, S. N. and Zhong, X. B.: P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity. Expert Opin. Drug Metab. Toxicol., 4: 439-452 (2008).
2. Saito, Y., Yamamoto, N., Katori, N., Maekawa, K., Fukushima-Uesaka, H., Sugimoto, D., Kurose, K., Sai, K., Kaniwa, N., Sawada, J., Kunitoh, H., Ohe, Y., Yoshida, T., Matsumura, Y., Saijo, N., Okuda, H. and Tamura, T.: Genetic polymorphisms and haplotypes of POR, encoding cytochrome P450 oxidoreductase, in a Japanese population. Drug Metab. Pharmacokinet., 26: 107-116 (2011).
3. Flück, C. E., Tajima, T., Pandey, A. V., Arlt, W., Okuhara, K., Verge, C. F., Jabs, E. W., Mendonça, B. B., Fujieda, K. and Miller, W. L.: Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat. Genet., 36: 228-230 (2004).
4. Fukami, M., Horikawa, R., Nagai, T., Tanaka, T., Naiki, Y., Sato, N., Okuyama, T., Nakai, H., Soneda, S., Tachibana, K., Matsuo, N., Sato, S., Homma, K., Nishimura, G., Hasegawa, T. and Ogata, T.: Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J. Clin. Endocrinol. Metab., 90: 414-426 (2005).
5. Fukami, M., Nishimura, G., Homma, K., Nagai, T., Hanaki, K., Uematsu, A., Ishii, T., Numakura, C., Sawada, H., Nakacho, M., Kowase, T., Motomura, K., Haruna, H., Nakamura, M., Ohishi, A., Adachi, M., Tajima, T., Hasegawa, Y., Hasegawa, T., Horikawa, R., Fujieda, K. and Ogata, T.: Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. J. Clin. Endocrinol. Metab., 94: 1723-1731 (2009).
6. Homma, K., Hasegawa, T., Nagai, T., Adachi, M., Horikawa, R., Fujiwara, I., Tajima, T., Takeda, R., Fukami, M. and Ogata, T.: Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. J. Clin. Endocrinol. Metab., 91: 2643-2649 (2006).
7. Huang, N., Pandey, A. V., Agrawal, V., Reardon, W., Lapunzina, P. D., Mowat, D., Jabs, E. W., Van Vliet, G., Sack, J., Flück, C. E. and Miller, W. L.: Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am. J. Hum. Genet., 76: 729-749 (2005).
8. Emoto, C., Murayama, N., Wakiya, S. and Yamazaki, H.: Effects of histidine-tag on recombinant human cytochrome P450 3A5 catalytic activity in reconstitution systems. Drug Metab. Lett., 3: 207-211 (2009).
9. Niwa, T., Murayama, N., Emoto, C. and Yamazaki, H.: Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Curr. Drug Metab., 9: 20-33 (2008).
10. Niwa, T., Murayama, N. and Yamazaki, H.: Comparison of the contributions of cytochromes P450 3A4 and 3A5 in drug oxidation rates and substrate inhibition. J. Health Sci., 56: 239-256 (2010).
11. Shinkyo, R., Kamakura, M., Ikushiro, S., Inouye, K. and Sakaki, T.: Biodegradation of dioxins by recombinant Escherichia coli expressing rat CYP1A1 or its mutant. Appl. Microbiol. Biotechnol., 72: 584-590 (2006).
12. Imai, T., Globerman, H., Gertner, J. M., Kagawa, N. and Waterman, M. R.: Expression and purification of functional human 17α-hydroxylase/17,20-lyase (P450c17) in Escherichia coli. Use of this system for study of a novel form of combined 17α hydroxylase/ 17,20-lyase deficiency. J. Biol. Chem., 268: 19681-19689 (1993).
13. Flück, C. E., Nicolo, C. and Pandey, A. V.: Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase. Fundam. Clin. Pharmacol., 21: 399-410 (2007).
14. Flück, C. E., Mullis, P. E. and Pandey, A. V.: Modeling of human P450 oxidoreductase structure by in silico mutagenesis and MD simulation. Mol. Cell. Endocrinol., 313: 17-22 (2009).
15. Marohnic, C. C., Panda, S. P., Martásek, P. and Masters, B. S.: Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase. J. Biol. Chem., 281: 35975-35982 (2006).